Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
G1 Therapeutics Inc
(NQ:
GTHX
)
7.150
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Sep 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
7.150
Bid (Size)
7.140 (212)
Ask (Size)
7.180 (13)
Prev. Close
7.150
Today's Range
7.150 - 7.150
52wk Range
1.080 - 7.190
Shares Outstanding
42,705,532
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Pharmacosmos Group and G1 Therapeutics Announce Successful Closing of Tender Offer
September 18, 2024
From
G1 Therapeutics
Via
GlobeNewswire
Pharmacosmos Group and G1 Therapeutics Announce Expiration of Hart-Scott-Rodino Waiting Period
September 05, 2024
From
G1 Therapeutics
Via
GlobeNewswire
Performance
YTD
+129.90%
+129.90%
1 Month
+0.28%
+0.28%
3 Month
+178.21%
+178.21%
6 Month
+49.90%
+49.90%
1 Year
+495.83%
+495.83%
More News
Read More
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GVP, PETQ, GTHX on Behalf of Shareholders
August 15, 2024
From
Halper Sadeh LLC
Via
GlobeNewswire
Why Is G1 Therapeutics (GTHX) Stock Up 66% Today?
August 07, 2024
Via
InvestorPlace
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Thoughtworks Holding, Inc. (Nasdaq – TWKS), PetIQ, Inc. (Nasdaq – PETQ), G1 Therapeutics, Inc. (Nasdaq – GTHX), GSE Solutions, Inc. (Nasdaq – GVP)
August 15, 2024
From
Brodsky & Smith LLC
Via
GlobeNewswire
G1 THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of G1 Therapeutics, Inc. - GTHX
August 09, 2024
From
Kahn Swick & Foti, LLC
Via
Business Wire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GTHX, PETQ on Behalf of Shareholders
August 09, 2024
From
Halper Sadeh LLC
Via
GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Thoughtworks Holding, Inc. (Nasdaq – TWKS), PetIQ, Inc. (Nasdaq – PETQ), G1 Therapeutics, Inc. (Nasdaq – GTHX), GSE Solutions, Inc. (Nasdaq – GVP)
August 08, 2024
From
Brodsky & Smith LLC
Via
GlobeNewswire
G1 Therapeutics Provides Second Quarter 2024 Financial Results and Operational Highlights
August 08, 2024
From
G1 Therapeutics
Via
GlobeNewswire
Dow Tumbles Over 200 Points; CVS Health Cuts Profit Forecast
August 07, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Crude Oil Jumps Over 3%; Upstart Shares Spike Higher
August 07, 2024
Via
Benzinga
Exposures
Fossil Fuels
Nasdaq Jumps 250 Points; Disney Earnings Beat Estimates
August 07, 2024
Via
Benzinga
Topics
Earnings
Exposures
Financial
GTHX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of G1 Therapeutics, Inc. Is Fair to Shareholders
August 07, 2024
From
Halper Sadeh LLC
Via
Business Wire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
August 07, 2024
Via
InvestorPlace
Pharmacosmos Group to Acquire G1 Therapeutics
August 07, 2024
From
G1 Therapeutics; Pharmacosmos
Via
GlobeNewswire
G1 Therapeutics to Release Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024
July 25, 2024
From
G1 Therapeutics
Via
GlobeNewswire
G1 Therapeutics Stock: The Undervalued Gem Poised for a 30% Revenue Surge by 2025
July 15, 2024
Via
InvestorPlace
Biotech Bombshell: G1 Therapeutics Stock Is Too Much of a Gamble
July 10, 2024
Via
InvestorPlace
Ball To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Tuesday
June 25, 2024
Via
Benzinga
Coffee Recall 2024: Over 250 Coffee Products Recalled Due to Botulism Fears
June 24, 2024
Via
InvestorPlace
Exposures
Product Safety
Ginkgo Bioworks Layoffs 2024: What to Know About the Latest DNA Job Cuts
June 24, 2024
Via
InvestorPlace
Topics
Workforce
Exposures
Layoff
Alnylam's Closely Watched Phase 3 Heart Disease Trial Of Vutrisiran Hits Primary Endpoint, Shares Surge
June 24, 2024
Via
Benzinga
Why Is Cancer-Focused G1 Therapeutics Stock Trading Lower On Monday?
June 24, 2024
Via
Benzinga
Why Is G1 Therapeutics (GTHX) Stock Down 56% Today?
June 24, 2024
Via
InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
June 24, 2024
Via
InvestorPlace
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.